

Jeffrey Louis Sugarman, M.D., Ph.D.

CURRICULUM VITAE

Business Address: 2725 Mendocino Ave
Santa Rosa, CA 95403
Phone: (707) 545-4537
Fax: (707) 545-6726

Education:

1987 University of California, Berkeley B.A. Neurobiology
1995 University of California, San Diego Ph.D. Biomedical Science
1996 University of California, San Diego M.D.

Board Certification:

1999 American Board of Pediatrics
2002 American Board of Dermatology
2008 American Board of Dermatology, Pediatric Dermatology Subspecialty

Training and Employment:

1996-1999 Pediatrics Residency, University of Washington
Children's Regional Hospital and Medical Center, Seattle
1999-2002 Dermatology Residency, University of California, San Francisco
1999-2002 San Francisco Neonatology Group, Newborn Hospitalist
2001-2002 Pediatric Dermatology Fellowship, University of California, San Francisco
2002-present Medical Director, Redwood Family Dermatology, Santa Rosa, CA
2002-2005 Solano Dermatology Associates, Pediatric and Adult Dermatology, Vallejo
2002-2003 Clinical Instructor, University of California, San Francisco, Department of Dermatology
2003-2009 Assistant Clinical Professor, University of California, San Francisco, Departments of Dermatology, Family and Community Medicine
2009-present Associate Clinical Professor, University of California, San Francisco, Departments of Dermatology, Family and Community Medicine
2002-present Staff physician Santa Rosa Memorial Hospital
2002-present Staff physician Sutter Medical Center in Santa Rosa
2004-present San Francisco General Hospital attending physician
2005-present Consultant to Dow Pharmaceutical Sciences
2007-present Clinical investigator, Solano Clinical Research

Honors and Awards:

2009 SCMA outstanding contribution to medicine in Sonoma County
2002 Alvin Jacobs Research Award, Society of Pediatric Dermatology
1988-1996 NIH/NIGMS Medical Scientist Training Program Fellowship Award
1987 Scholastic Honors, University of California, Berkeley, College of Letters and Science

Updated 9/09

1987 High Honors in Neurobiology, University of California, Berkeley

Professional Activities:

Medical and Professional Societies

1996-present American Academy of Pediatrics
1999-present American Academy of Dermatology
2000-present Society for Pediatric Dermatology
2002-present California Medical Association
2002-present Sonoma County Medical Association
2002-2009 Sonoma County Dermatology Society
2005-present American Contact Dermatitis Society
2009-present Northern California Dermatology Society, board of directors
2009-present California Dermatology Association

Service to Professional Organizations

2002-present Editorial Board Member, Sonoma County Medical Association
2004-present SCMA Professional Standards and Conduct (PSC) Committee member
2004-2007 Society for Pediatric Dermatology Awards and Goals Committee
2006 Organizer and moderator, Society for Pediatric Dermatology 18th Annual Pre-AAD Meeting
2006-present Chairman of Society for Pediatric Dermatology Research Task Force
2007-present Board of Directors, Sonoma County Medical Association
2009 Secretary, executive board, Sonoma County Medical Association
2009 Organizer and moderator, Society for Pediatric Dermatology First Annual Research Forum

Reviewer for the following medical journals:

Pediatric Dermatology (2005-present)
Archives of Dermatology (2005 to present)
European Journal of Dermatology (2006 to present)
Journal of the American Academy of Dermatology (2008-present)

Invited Lectures and Presentations:

Local and Regional

9/09 Epidermal Nevus Syndromes Update
UCSF Grand Rounds
San Francisco, CA

- 9/09 Epidermal Nevus Syndromes Update
California Society of Dermatology Annual Meeting
San Diego, CA
- 9/09 The skin barrier and atopic dermatitis. Implications for treatment
Houston, TX
- 8/08 Advances in the Treatment of Acne Vulgaris
Portland, OR
- 7/08 Update on epidermal nevus syndromes
Dartmouth Grand Rounds,
Hanover, NH
- 4/08 Acne Vulgaris, a customized overview
Seattle, WA
- 11/07 Visual Clues to Differential Diagnosis in Pediatric Dermatology
37th Annual Fall Conference, Children's Hospital Oakland
Monterrey, CA
- 11/07 Lumps and Bumps; What Embryology Teaches us
37th Annual Fall Conference, Children's Hospital Oakland
Monterrey, CA
- 11/07 The Importance of the Skin Barrier in Atopic Dermatitis
37th Annual Fall Conference, Children's Hospital Oakland
Monterrey, CA
- 9/07 Update on Acne in Ethnic Skin
Santa Rosa, CA
- 9/06 Atopic Dermatitis Diagnosis and Treatment
Hopland, CA
- 2/06 Atopic Dermatitis Management Pearls
Fresno, CA
- 2/06 Atopic Dermatitis Management Strategies
Stockton, CA
- 11/05 Atopic Dermatitis Review
Santa Rosa, CA
- 10/05 Acne pathogenesis and treatment
Santa Rosa, CA
- 10/05 Drug reactions in Children
Sonoma Development Center
Glen Ellen, CA
- 9/05 Therapeutic Pearls for Atopic Dermatitis Management
Marin General Hospital Grand Rounds
Marin, CA
- 7/05 Therapeutic Pearls for Atopic Dermatitis Management
Bend, Oregon
- 7/05 Atopic Dermatitis Management Update
Walnut Creek, CA

Updated 9/09

- 7/05 Update on Epidermal Nevus Syndromes
Oregon Dermatology Society Meeting
Sun River, Oregon
- 7/05 Therapeutic Pearls for Atopic Dermatitis Management
Oregon Dermatology Society Meeting
Sun River, Oregon
- 6/05 Therapeutic Pearls for Refractory Atopic Dermatitis
38th Annual Advances and Controversies in Clinical Pediatrics
San Francisco, CA
- 5/05 Atopic Dermatitis Diagnosis and Treatment
Eugene, Oregon
- 5/05 Atopic Dermatitis Diagnosis and Treatment
Grand Round Childrens Hospital Oakland
Oakland, CA
- 4/05 Differential diagnosis of foot dermatitis and toenail dystrophy
San Francisco, CA
- 2/05 Pathophysiology of Acne Vulgaris and Implications for Treatment
Ukiah, CA
- 9/04 Atopic Dermatitis: Diagnosis and Treatment
Marin Nurse Practitioners Association CME, Marin, CA
- 6/04 The Changing Landscape of Atopic Dermatitis Treatment
Portland, Oregon
- 5/04 Evaluation and treatment of melanocytic lesions and skin cancers
Sonoma Developmental Center, Glen Ellen, CA
- 3/04 Update on Pediatric Dermatology Diagnosis and Therapeutics
Center for Well-Being, Santa Rosa, CA
- 2/04 Assessment and Treatment of Common Dermatologic Problems
Sonoma Developmental Center, Glen Ellen, CA
- 2/04 Understanding the Changing Landscape of Atopic Dermatitis Treatment
California Association (Region 5) of Nurse Practitioners, Santa Rosa, CA
- 2/04 Differential Diagnosis of Tinea Pedis and Onychomycosis
Sacramento Valley Podiatric Society meeting
Sacramento, CA
- 2/04 Pathophysiology of Acne Vulgaris and Implications for Treatment
Sutter Hospital Grand Rounds, Santa Rosa, CA
- 11/03 Understanding the Changing Landscape of Atopic Dermatitis Treatment
Portland, Oregon
- 4/03 When It's Not Tinea or Eczema: Common, Uncommon, and Rare Mimickers of
Common Dermatoses
Santa Rosa Memorial Hospital Grand Rounds, Santa Rosa, CA
- 2/03 Differential Diagnosis of Fungal Infection of the Nail and Foot
California Podiatric Medical Association, Napa, CA
- 12/02 Assessment and Treatment of Common Dermatologic Problems
Sonoma Developmental Center, Glen Ellen, CA

Updated 9/09

- 8/02 Cutaneous Eruptions in the Newborn
Sutter Hospital, Pediatric Grand Rounds, Santa Rosa, CA
- 6/02 The objective severity assessment in atopic dermatitis (OSAAD) score.
Resident expert talk. University of California, Department of Dermatology,
San Francisco, CA
- 5/02 Introduction to Pediatric Dermatology Pediatric Core Curriculum California
College of Podiatric Medicine, San Francisco, CA
- 11/01 Atopic Dermatitis: Immune Mechanisms
Grand Rounds UCSF, Department of Dermatology,
San Francisco, CA
- 10/01 Hyper IgE Syndrome. University of California, Department of Pediatrics,
Pediatric Morning Lecture Series. San Francisco, CA
- 9/01 The Role of the Barrier in Atopic Dermatitis. University of California,
San Francisco, Allergy and Immunology Conference. San Francisco, CA
- 5/01 The Immunopathogenesis of Atopic Dermatitis. Resident expert talk.
University of California, Department of Dermatology, San Francisco, CA
- 5/01 Introduction to Pediatric Dermatology. Pediatric Core Curriculum. California
College of Podiatric Medicine, San Francisco, CA
- 5/99 A Case of Neonatal Seizures. Grand Rounds. Children's Hospital and Medical
Center, Seattle, WA
- 3/99 Management of Tinea Capitis in the Pediatric Population. Pediatric Special
Topics: Harborview Medical Center, Seattle, WA
- 1/95 Cell Cycle Control in Myloid Cells. Regulation of *cdc2*.
PhD. thesis defense. Center for Molecular Medicine, San Diego, CA
- 11/94 Identification of a Cell Type-Specific and E2F-Independent Mechanism for
Repression of *cdc2* Transcription. Center for Molecular Medicine Seminar
Series. San Diego, CA

National Presentations

- 11/09 Lumps and Bumps. Society of Dermatology Physician Assistants Annual
Meeting
Scottsdale, AZ
- 11/09 Pediatric Dermatology Pearls. Society of Dermatology Physician Assistants
Annual Meeting
Scottsdale, AZ
- 7/09 Moderator, Research Forum
35th Annual meeting for the Society for Pediatric Dermatology
Philadelphia, PA
- 7/07 Moderator, Cases in Search of a Diagnosis
33rd Annual meeting for the Society for Pediatric Dermatology
Chicago, IL
- 3/06 Moderator, Cases in Search of a Diagnosis
18th Annual pre-AAD Society for Pediatric Dermatology Meeting
San Francisco, CA

Updated 9/09

- 2/06 Update on Atopic Dermatitis
Oahu, Hawaii
- 9/05 Pediatric Therapeutics
Women's and Pediatric Dermatology Seminar
San Francisco, CA
- 9/05 Update on the Management Warts and Molluscum
Women's and Pediatric Dermatology Seminar
San Francisco, CA
- 8/04 Update on Atopic Dermatitis Diagnosis and Treatment
Skin Disease Education Foundation Dermatology Seminar, Santa Fe, NM
- 10/02 Objective Severity Assessment in Atopic Dermatitis (OSAAD) Score.
Bioengineering for the New Millenium. The 2002 US Symposium of The
International Society for Bioengineering and the Skin ISBS. Baltimore,MD
- 9/02 Update on Atopic Dermatitis.
Skin Disease Education Foundation Dermatology Seminar, Santa Fe, NM
- 7/02 Objective Severity Assessment in Atopic Dermatitis (OSAAD).
Society for Pediatric Dermatology, Annapolis, MD
- 1/02 The Role of Infection in Atopic Dermatitis.
XXVI Annual Hawaii Dermatology Seminar, Maui, HI
- 7/00 A Case of Bullous Mastocytosis. Case of the year, Society for Pediatric
Dermatology Annual Meeting, Santa Fe, NM
- 3/00 A Case of Juvenile Hyaline Fibromatosis.
Case of the Year, Society for Pediatric Dermatology, Pre-American Academy of
Dermatology Meeting, San Francisco, CA

International Presentations:

- 7/04 The Objective Severity Assessment of Atopic Dermatitis (OSAAD) Score has
Excellent Correlation Between Observers, Rome, Italy
- 10/01 Streptococcal Infection in Atopic Dermatitis. An Emerging Pathogen. IX
World Congress of Pediatric Dermatology, Cancun, Mexico

Community and Public Service:

- 2008-present Sonoma County Specialty Access Taskforce
- 2004-present Director and founder of the Northern California Regional Dermatology Center
(NCRDC) for the management of skin diseases for the uninsured and
underinsured.
Healdsburg CA.
- 2003-2005 Presentations to Children's Diabetes Association. Cutaneous Manifestations of
Diabetes. Santa Rosa, CA

Updated 9/09

- 2003-07 Annual lectures to Analy High School Human skin physiology class on photoprotection, skin cancer and acne. Sebastopol, CA
- 2003 Sonoma County Smallpox Task Force
- 2001-2002 Assistant Medical Director, Skin Disease Foundation. Camp Wonder.

Teaching:

1. Attending in the Pediatric Dermatology Clinic, University of California, San Francisco, at Mount Zion. A minimum of 50 hours annually for the academic years 2002-2009 (and anticipated for 2010) was spent precepting dermatology residents, pediatrics residents, pediatric dermatology fellows, and medical students.
2. A minimum of 500 hours annually 2009 (and anticipated in 2010) is spent precepting UCSF/Sutter family practice residents and medical students in private practice dermatology and community clinic settings.
3. Director and attending, University of California, Santa Rosa Sutter Family Practice Residency Program Outpatient Dermatology Clinic (2002-present). A minimum of 50 hours annually was spent precepting family practice residents during this time.
4. Design and implementation of didactic lecture series in dermatology for UCSF/Sutter family practice residents 2006-2009
5. Clinical Unknowns in Pediatric Dermatology Lecture. Dermatology Core Curriculum. University of California, San Francisco, Department of Dermatology. 2001 to 2002
6. Introduction to Pediatric Dermatology Lecture. Pediatric Core Curriculum. California College of Podiatric Medicine. 2001
7. Informal clinical teaching in dermatology of medical students, interns and residents. University of California, San Francisco, Department of Dermatology. 1999 to 2002
8. Clinical teaching in pediatrics of medical students, pediatric interns and residents. Children's Hospital and Regional Medical Center, and the University of Washington in Seattle. 1996-1999

Clinical Research Projects and Training:

1. Medical Monitor: Phase 2b clinical trial topical treatment of atopic dermatitis (2009).
2. Medical Monitor: Phase 3 clinical trial topical treatment of onychomycosis (2009).
3. Medical Monitor: Phase 3 trial of Adapalene 0.3% lotion for the treatment of mild-moderate acne vulgaris (2008).
4. Medical Monitor: Phase 2b trial of Azithromycin treatment for moderate to severe acne vulgaris (2008).
5. Principle Investigator: Comparison of two dosing regimens for Azithromycin treatment for moderate to severe acne vulgaris (2008).
6. Principle investigator: Efficacy, Safety and Tolerability of XXX Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL). A phase II Study Comparing Topical Treatment with Two Dosage Regimens of XXX Cream and XXX (YYY) X Cream in Adults and Children with Impetigo or SITL (2008)
7. Sub-investigator. Phase 3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two dosing Regimens of XXX to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis. (2008).
8. Sub-investigator. Dengue fever: Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US (2008).
9. Sub investigator. Flu vaccine: Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Administered with and without a XXX in Healthy Adults (2007).
10. NIH Human Participants Protection Education for Research Training (2007)
11. Basic collaborative research investigating the genetic defects in nevus sebaceus syndrome and nevus comedonicus syndrome (2006-present)
12. Principle Investigator: Investigator blind, controlled phase 4 study comparing a mid-strength topical steroid to a non-steroid barrier repair cream for the treatment of moderate to severe atopic dermatitis in children (2006)
13. Principal Investigator: The objective severity assessment of atopic dermatitis (OSAAD) score reflects disease severity over time (2006).

14. Principal Investigator: OSAAD Interobserver variability study. The objective severity assessment of atopic dermatitis (OSAAD) score has excellent correlation between observers and lower variance and better correlation between observers than the SCORAD (2005).
15. Sub-investigator. Epidermal barrier dysfunction affects the growth of children with AD (2005).
16. Principal Investigator: The Objective Severity Assessment of Atopic Dermatitis (OSAAD) Score: An objective measure utilizing permeability barrier function and stratum corneum hydration, with computer-assisted estimates for extent of disease (2003)

Publications:

Original Articles:

1. **Sugarman, JL, Pope, E, Paller, A.** Impediments to research in pediatric dermatology. Pediatric Dermatology (in press)
2. **Sugarman, JL, Parish, L.** A Topical Physiologic, Lipid-Based, Barrier Repair Formulation (EpiCeram™ Cream) is Highly-Effective Monotherapy for Moderate-To-Severe Pediatric Atopic Dermatitis Journal of Drugs in Dermatology (in press) 2009
3. **Sugarman, JL.** Specialty access initiative in Sonoma County. Sonoma Medicine 60(4) 29-31, 2009
4. **Sugarman, JL,** and Pfeifer, K. Specialty Care for the Un- and Underinsured in Sonoma County. Sonoma Medicine 58(3):13-16, 2007
5. Marqueling AL, Gilliam AE, Prendiville J, Zvulunov A, Antaya RJ, **Sugarman JL**, Pang ML, Lee P, Eichenfield L, Metz B, Goldberg GN, Phillips RJ, Frieden IJ. Keratosis pilaris rubra: a common but underrecognized condition. Arch Dermatol. 2006 Dec;142(12):1611-6. ML, Lee P, Eichenfield L, Metz B, Goldberg GN, Phillips RJ, Frieden IJ. Keratosis pilaris rubra: a common but underrecognized condition. Arch Dermatol. 2006 Dec;142(12):1611-6
6. **Sugarman, JL.** Can a Molecular Fingerprint Reveal a Mole's Biologic Behavior? Sonoma Medicine 56(1):16-17, 2005.
7. **Sugarman, JL.,** Fluhr, JW., Fowler, AJ., Bruckner, T., Diepgen T., Williams, ML. "The Objective Severity Assessment of Atopic Dermatitis (OSAAD) Score: An objective measure utilizing permeability barrier function and stratum corneum

- hydration, with computer-assisted estimates for extent of disease.” Arch Dermatol. 139(11):1417-22, 2003.
8. **Sugarman JL**. Sun Protection in Children. Sonoma Medicine. 54:18-20, 2003.
 9. **Sugarman, J.L.**, Mauro, T., Frieden, I.J. “Treatment of an Ulcerated Hemangioma with Platelet Derived Growth Factor.” Arch Dermatol. 138:314-316, 2002.
 10. Babb, V.L., **Sugarman, J.L.**, Scavetta, R., Wang, S.J., Born, T.L., Glass, C.K., Schonthal, A.H. “Positive Regulation of *cdc2* Gene Activity by Protein Phosphatase 2A”. Journal of Biological Chemistry 271(11) 5988-5992.1995
 11. **Sugarman, J.L.**, Schonthal, A.H., Glass, C.K. “Identification of a Cell-Type Specific and E2F-Independent Mechanism for Repression of *cdc2* Transcription.” Molecular and Cellular Biology 15(6): 3282-3290. 1995
 12. **Sugarman, J.L.**, Thompson, A.R., Glass, C.K., and Schonthal, A.H. “Differential Effects of Two Types of Tumor Promoters, Okadaic Acid and 12-O-Tetradecanoyl-Phorbol-13-Acetate, on Growth and Differentiation of Human Myeloid Leukemia Cells”. Molecular and Cellular Differentiation 3(1): 51-71. 1995
 13. Smarda, J., **Sugarman, J.L.**, Glass, C.K., and Lipsick, J. “Retinoic Acid Receptor- α Suppresses Transformation by *v-myb*.” Molecular and Cellular Biology 15(5): 2474-2481. 1995
 14. Kurokawa, R., DiRenzo, J., Boehm, M., **Sugarman, J.L.**, Gloss, B., Rosenfeld, M.G., Heyman, R.A., and Glass, C.K. 1994. "Receptor Polarity and Allosteric Control of Ligand Binding Dictate the Transcriptional Responses to Retinoic Acid." Nature 371: 528-531
 15. Anderson, B., Schonemann, M.D., Pearse, R.V., **Sugarman, J.L.**, and Rosenfeld, M.G. 1993. "Brn-5 is a Divergent POU Domain Factor Expressed in Layer IV of the Neocortex." Journal of Biological Chemistry 268: 23390-23398
 16. **Sugarman, J.L.**, Schonthal, A.H. 1992. "Down Regulation of Histone H1 Kinase Activity and Hypophosphorylation of the Retinoblastoma Protein During Induced Differentiation of Human Myeloid Leukemia Cells." Acta Medica Romana 30 (3/4): 191-194
 17. Schonthal, A.H., **Sugarman, J.L.**, Brown, J.H., Hanley, M.R., and Feramisco, J.R. 1991. "Regulation of *c-fos* and *c-jun* Protooncogene Expression by the Ca²⁺-ATPase Inhibitor Thapsigargin". PNAS 88: 7096-7100

Invited Articles:

1. Gamboa DG, **Sugarman JL**. An update on selected connective tissue diseases in adolescents. Curr Opin Pediatr. 413-8, 2008
2. **Sugarman JL**. The epidermal barrier in atopic dermatitis. Semin Cutan Med Surg. 108-14, 2008
3. **Sugarman, J.L.** Epidermal Nevus Syndromes. Semin Cutan Med and Surg. 26(4):221-230, 2007
4. **Sugarman, J.L.** Epidermal Nevus Syndromes. Semin in Cutan Med and Surg. 23:145-157, 2004

Letters and Editorials:

1. **Sugarman, JL**. Telemedicine: The Electronic Black Bag. Sonoma Medicine 59(1) 2008
2. **Sugarman JL**, McCalmont TH, Frieden IJ, Dover J, Arndt K. Gigantic metamerich seborrheic keratosis. Plast Reconstr Surg 15;111(5):1775-6, 2003
3. Geisse, J., **Sugarman, JL**. The Surgical Management of Spitz Nevi, Commentary. Dermatol Surg 28 (11):1069, 2002

Book Chapters

1. **Sugarman, JL**. Epidermal Nevus Syndromes: an overview. In: Phakomatoses & Hamartoneoplastic Syndromes. Ruggieri, Martino; Pascual Castroviejo, Ignacio; Di Rocco, Concezio (Eds.) SpringerWein, New York. 2008
2. **Sugarman, JL**. Nevus Comedonicus Syndrome. In: Phakomatoses & Hamartoneoplastic Syndromes. Ruggieri, Martino; Pascual Castroviejo, Ignacio; Di Rocco, Concezio (Eds.) SpringerWein, New York. 2008
3. Ruggieri, M and **Sugarman, JL**. ILVEN (Inflammatory Linear Verrucous Epidermal Nevus). In: Phakomatoses & Hamartoneoplastic Syndromes Ruggieri, Martino; Pascual Castroviejo, Ignacio; Di Rocco, Concezio (Eds.) SpringerWein, New York. 2008

4. **Sugarman JL** and Frieden IJ. Epidermal Nevus Syndromes. In: Neurocutaneous Syndromes. Roach and Van Miller editors.. Cambridge: Cambridge University Press; p. 88-104, 2004

Abstracts:

1. A Topical Physiologic, Lipid-Based, Barrier Repair Formulation (EpiCeram™ Cream) is Highly-Effective Monotherapy for Moderate-To-Severe Pediatric Atopic Dermatitis
Journal of Investigative Dermatology, 2008
2. Evaporative caloric losses due to an impaired permeability barrier may contribute to growth failure in children with atopic dermatitis
Journal of Investigative Dermatology. 2006
3. The objective severity assessment of atopic dermatitis (OSAAD) score: a validated score with low inter-observer variability.
Journal of Investigative Dermatology. 2005
4. The objective severity assessment of atopic dermatitis (OSAAD) score has excellent correlation between observers and lower variance and better correlation between observers than the SCORAD.
Pediatric dermatology 21:403, 2004
5. Streptococcal Infection in Atopic Dermatitis. An Emerging Pathogen. IX
World Congress of Pediatric Dermatology, Cancun, Mexico. October 2001
6. An unusual mechanism for cell cycle arrest involving the basal promoter of *cdc2*.
American Association for Cancer Research Special Conference on the Transcriptional Control of Cell Growth and Differentiation, Chatham, MA. October 1994
7. Cell cycle control during growth arrest and differentiation of human myeloid cells. 46th Annual Symposium on Fundamental Cancer Research on Mechanisms for Cell Growth and Differentiation., Houston, TX., October 1993
8. Regulation of histone H1 kinase activity during retinoic acid induced growth arrest of human myeloid leukemia cells. American Association for Cancer Research, Alberta, Canada. March 1993
9. Down regulation of histone H1 kinase activity and hypophosphorylation of the retinoblastoma protein during induced differentiation of human myeloid leukemia cells. American Association for Cancer Research, Rome, Italy. April 1992

10. Regulation of *c-fos* and *c-jun* protooncogene expression by the Ca²⁺ -ATPase inhibitor thapsigargin. Annual Medical Scientist Training Program Conference, Aspen, CO. July 1991

Doctoral Dissertation

Sugarman, J.L. Transcriptional Control of *cdc2* During Cell Cycle Arrest in Human Myeloid Leukemia Cells. University of California Press. 1995

Poster Exhibits

1. A Topical Physiologic, Lipid-Based, Barrier Repair Formulation (EpiCeram® Cream) is Safe and Effective Monotherapy for both Mild-To-Moderate and Moderate-To-Severe Pediatric Atopic Dermatitis
Society for Pediatric Dermatology 2008
2. A Topical Physiologic, Lipid-Based, Barrier Repair Formulation (EpiCeram™ cream) is Highly-Effective Monotherapy for Moderate-To-Severe Pediatric Atopic Dermatitis
International Investigative Dermatology, 2008
3. Evaporative caloric losses due to an impaired permeability barrier may contribute to growth failure in children with atopic dermatitis
Society of Investigative Dermatology. 2006
4. The objective severity assessment of atopic dermatitis (OSAAD) score: a validated score with low inter-observer variability.
Society for Investigative Dermatology. 2005
5. The objective severity assessment of atopic dermatitis (OSAAD) score has excellent correlation between observers and lower variance and better correlation between observers than the SCORAD.
World Congress of Pediatric Dermatology. July 2004
6. The objective severity assessment in atopic dermatitis (OSAAD). American Academy of Dermatology National Meeting, San Francisco, CA. March 2003

7. A retrospective review of Streptococcal infections in children with atopic dermatitis. Society for Pediatric Dermatology, Baltimore MD. July 2002
8. An unusual mechanism for cell cycle arrest involving the basal promoter of *cdc2*. American Association for Cancer Research Special Conference on the Transcriptional Control of Cell Growth and Differentiation, Chatham, MA. October 1994
9. Cell cycle control during growth arrest and differentiation of human myeloid cells. 46th Annual Symposium on Fundamental Cancer Research on Mechanisms for Cell Growth and Differentiation, Houston, TX. October 1993
10. Regulation of histone H1 kinase activity during retinoic acid induced growth arrest of human myeloid leukemia cells. American Association for Cancer Research, Alberta, Canada. March 1993
11. Regulation of *c-fos* and *c-jun* protooncogene expression by the Ca²⁺-ATPase inhibitor thapsigargin. Annual Medical Scientist Training Program Conference, Aspen, CO. July 1991